<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00875836</url>
  </required_header>
  <id_info>
    <org_study_id>R01DA026782</org_study_id>
    <secondary_id>R01DA026782</secondary_id>
    <secondary_id>DPMCDA</secondary_id>
    <nct_id>NCT00875836</nct_id>
  </id_info>
  <brief_title>Buspirone Treatment for Marijuana Dependence</brief_title>
  <official_title>Buspirone Treatment for Marijuana Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Marijuana is the most commonly used illicit drug, yet few clinical trials have evaluated
      pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy of
      buspirone for reducing marijuana use in marijuana-dependent adults. A contingency management
      (CM) intervention and motivational enhancement therapy (MET) will be incorporated to
      encourage study engagement and retention. It is hypothesized that buspirone combined with MET
      and CM will reduce the percent of marijuana-positive urine drug screen results in
      marijuana-dependent individuals as compared to a placebo treatment combined with MET and CM.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Marijuana-negative Urine Drug Screens (UDS)</measure>
    <time_frame>Participants provided a once-weekly urine sample for twelve weeks</time_frame>
    <description>Participants submitted a urine sample weekly. Percentage of marijuana negative urine samples were calculated per group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retention in the Study</measure>
    <time_frame>participants were followed for twelve weeks</time_frame>
    <description>Number of days subjects remained active in the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Marijuana Craving</measure>
    <time_frame>8 Weeks</time_frame>
    <description>The Marijuana Craving Questionnaire (MCQ) is intended to measure marijuana craving in adults. It measures symptoms on four subscales: expectancy, purposefulness, emotionality, and compulsivity. The scale rates individual items from 1 (least craving) - 7 (most craving) with a composite scoring range of 12-84 and possible subscale scoring range of 3-21. It was administered weekly- reported here is the mean composite score across the 8 week treatment course.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">175</enrollment>
  <condition>Marijuana Dependence</condition>
  <arm_group>
    <arm_group_label>Buspirone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buspirone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buspirone</intervention_name>
    <description>Flexible dose, up to 60 mg daily</description>
    <arm_group_label>Buspirone</arm_group_label>
    <other_name>Buspar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Flexible dose, up to 60 mg daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must meet DSM-IV criteria for marijuana dependence.

          -  Must be between the ages of 18 and 65 years.

          -  If female and of childbearing potential, must agree to use acceptable methods of birth
             control for the duration of the trial.

          -  Must consent to random assignment, and be willing to commit to psychosocial behavioral
             and medication treatment.

          -  Must be able to read and provide informed consent.

        Exclusion Criteria:

          -  Women who are pregnant, nursing, or plan to become pregnant during the course of the
             study.

          -  Must not have a history of or current psychotic disorder, bipolar disorder, or eating
             disorder.

          -  Must not pose a current suicidal or homicidal risk.

          -  Must not meet current criteria for major depression.

          -  Must not have evidence or history of serious hematologic, endocrine, cardiovascular,
             pulmonary, renal, gastrointestinal or neurologic disease.

          -  Must not require concomitant therapy with psychotropic medication.

          -  Must not be currently dependent on other substances, with the exception of nicotine or
             caffeine.

          -  Hypersensitivity to buspirone or any other product component.

          -  Patients who, in the investigator's opinion, would be unable to comply with study
             procedures or assessments, or would be unacceptable study candidates (e.g., poses
             threat to staff).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aimee McRae-Clark, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2009</study_first_submitted>
  <study_first_submitted_qc>April 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2009</study_first_posted>
  <results_first_submitted>September 21, 2015</results_first_submitted>
  <results_first_submitted_qc>February 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 9, 2016</results_first_posted>
  <last_update_submitted>July 8, 2016</last_update_submitted>
  <last_update_submitted_qc>July 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Aimee McRae-Clark</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Marijuana</keyword>
  <keyword>Buspirone</keyword>
  <keyword>Contingency management</keyword>
  <keyword>Motivational enhancement therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buspirone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants recruited between November 2009 and March 2014 primarily through media and internet advertisements.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Buspirone</title>
          <description>Buspirone: Flexible dose up to 60 mg/day</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Flexible dose up to 60mg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Buspirone</title>
          <description>Buspirone: 30 mg capsules twice daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: 30 mg capsules twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="88"/>
            <count group_id="B2" value="87"/>
            <count group_id="B3" value="175"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Marijuana-negative Urine Drug Screens (UDS)</title>
        <description>Participants submitted a urine sample weekly. Percentage of marijuana negative urine samples were calculated per group.</description>
        <time_frame>Participants provided a once-weekly urine sample for twelve weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buspirone</title>
            <description>Buspirone: Flexible dose up to 60 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Flexible dose up to 60mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Marijuana-negative Urine Drug Screens (UDS)</title>
          <description>Participants submitted a urine sample weekly. Percentage of marijuana negative urine samples were calculated per group.</description>
          <units>percentage of UDS</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>UDS samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1056"/>
                <count group_id="O2" value="1044"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Retention in the Study</title>
        <description>Number of days subjects remained active in the study</description>
        <time_frame>participants were followed for twelve weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buspirone</title>
            <description>Buspirone: Flexible dose up to 60 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Flexible dose up to 60mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Retention in the Study</title>
          <description>Number of days subjects remained active in the study</description>
          <units>Day</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="18" upper_limit="91"/>
                    <measurement group_id="O2" value="84" lower_limit="14" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Marijuana Craving</title>
        <description>The Marijuana Craving Questionnaire (MCQ) is intended to measure marijuana craving in adults. It measures symptoms on four subscales: expectancy, purposefulness, emotionality, and compulsivity. The scale rates individual items from 1 (least craving) – 7 (most craving) with a composite scoring range of 12-84 and possible subscale scoring range of 3-21. It was administered weekly- reported here is the mean composite score across the 8 week treatment course.</description>
        <time_frame>8 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buspirone</title>
            <description>Buspirone: Flexible dose up to 60 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Flexible dose up to 60mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Marijuana Craving</title>
          <description>The Marijuana Craving Questionnaire (MCQ) is intended to measure marijuana craving in adults. It measures symptoms on four subscales: expectancy, purposefulness, emotionality, and compulsivity. The scale rates individual items from 1 (least craving) – 7 (most craving) with a composite scoring range of 12-84 and possible subscale scoring range of 3-21. It was administered weekly- reported here is the mean composite score across the 8 week treatment course.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6" lower_limit="27.0" upper_limit="32.2"/>
                    <measurement group_id="O2" value="28.4" lower_limit="25.8" upper_limit="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Buspirone</title>
          <description>Buspirone: Flexible dose up to 60 mg/day</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Flexible dose up to 60mg/day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="61" subjects_affected="36" subjects_at_risk="88"/>
                <counts group_id="E2" events="35" subjects_affected="23" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus/allergies/flu</sub_title>
                <counts group_id="E1" events="19" subjects_affected="13" subjects_at_risk="88"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="87" subjects_affected="43" subjects_at_risk="88"/>
                <counts group_id="E2" events="83" subjects_affected="40" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="19" subjects_affected="11" subjects_at_risk="88"/>
                <counts group_id="E2" events="32" subjects_affected="24" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness or lightheaded</sub_title>
                <counts group_id="E1" events="44" subjects_affected="36" subjects_at_risk="88"/>
                <counts group_id="E2" events="17" subjects_affected="11" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="88"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="55" subjects_affected="28" subjects_at_risk="88"/>
                <counts group_id="E2" events="46" subjects_affected="27" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="88"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety or Depression</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Congestion</sub_title>
                <counts group_id="E1" events="26" subjects_affected="19" subjects_at_risk="88"/>
                <counts group_id="E2" events="23" subjects_affected="18" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations included significant attrition during the course of the 12-week trial, difficulty with UCT interpretation due to the long excretion half-life of marijuana in urine, and likelihood that the genetic analysis was underpowered.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Aimee McRae-Clark</name_or_title>
      <organization>MUSC</organization>
      <phone>843.792.5216</phone>
      <email>mcraeal@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

